Warfarin Dose Management for INR 1.9
For an INR of 1.9 (assuming a target range of 2.0-3.0), you should increase the warfarin dose by approximately 5-20% of the total weekly dose. 1
Rationale for Dose Adjustment
An INR of 1.9 falls just below the therapeutic range of 2.0-3.0, indicating subtherapeutic anticoagulation that increases thromboembolism risk. 1
- The FDA labeling explicitly states that warfarin dosing should be adjusted based on PT/INR response, with most patients maintained on 2-10 mg daily. 1
- For INRs slightly out of range, dose adjustments should alter the total weekly dose by 5-20%. 2
Evidence-Based Management Strategy
When to Adjust vs. Watchful Waiting
Recent high-quality evidence provides nuanced guidance:
- A 2022 study of 45,351 slightly out-of-range INRs found that dose changes resulted in only marginally better outcomes than watchful waiting (60.0% vs 58.9% probability of next INR in range, p=0.024), a difference unlikely to be clinically important. 3
- However, a 2009 study demonstrated that optimal warfarin management involves changing the dose when INR is ≤1.7 or ≥3.3, which would predict improved time in therapeutic range from 68% to 74%. 4
Practical Approach for INR 1.9
Given that 1.9 is borderline subtherapeutic:
- If the patient has been stable with consistent INRs in range for months, you may consider continuing the same dose with repeat testing in 1-2 weeks. 5, 3
- If the patient has had recent INR instability, is at high thrombotic risk (mechanical valve, recent VTE, atrial fibrillation with high stroke risk), or this represents a downward trend, increase the weekly dose by 5-10%. 1, 2, 4
Dose Adjustment Calculation
To increase the dose by 5-10%: 2
- Calculate total weekly warfarin dose
- Multiply by 1.05-1.10
- Redistribute across the week
- Example: If taking 5 mg daily (35 mg/week), increase to 36.75-38.5 mg/week (approximately 5 mg six days, 7.5 mg one day)
Follow-Up Monitoring
Recheck INR in 1-2 weeks after any dose adjustment or decision to continue the same dose. 1, 2
- The FDA labeling emphasizes that intervals between INR determinations should be based on patient reliability and response to warfarin. 1
- More frequent monitoring (2-4 times weekly) is appropriate when making dose adjustments. 2
Critical Considerations
Do not bridge with low-molecular-weight heparin for a single subtherapeutic INR of 1.9 in most patients. 6
- Bridging is not warranted unless the patient has extremely high thrombotic risk (e.g., mechanical mitral valve with prior thromboembolism). 6
Avoid making dose changes for every minor INR fluctuation, as this can paradoxically worsen INR control. 5, 4
- A 2010 randomized trial showed no significant difference in 2-week follow-up INRs between single-dose adjustments versus no adjustment for occasional out-of-range values (60% vs 56% in range, OR 1.17,95% CI 0.59-2.30). 5